Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06700841 Cream in Mild to Moderate Atopic Dermatitis
NCT03903822Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in atopic dermatitis (AD) (8 arms), sponsored by Pfizer. Primary endpoint: Percent Change From Baseline in Eczema Area and Severity Index Total Score at 6 weeks. Started May 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03903822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903822.